Information Provided By:
Fly News Breaks for May 18, 2017
NLNK
May 18, 2017 | 08:07 EDT
SunTrust analyst Peter Lawson recommends buying NewLink on weakness after preliminary efficacy data on its GDC-0919 treatment showed 9% partial responses and 24% stable disease. The analyst says that "evidence is mounting" that IDOs such as GDC-0919 are more effective in earlier stages of cancer treatment than the patients who participated in this trial represented. As a result, he does not think the efficacy data from this trial was "informative." The analyst recommends buying the stock on weakness and keeps a Buy rating on NewLink.
News For NLNK From the Last 2 Days
There are no results for your query NLNK
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.